Company Research Report: BIOTYPE GmbH

Company Overview

• Name: BIOTYPE GmbH

• Mission: BIOTYPE is committed to advancing precision medicine through products and services designed for the robust analysis and interpretation of clinical biomarkers. The aim is to support easy access to precision medicine anywhere, anytime, and for everyone.

• Founded: 1999

• Founders: No information is available

• Key People: No information is available

• Headquarters: No information is available

• Number of Employees: No information is available

• Revenue: No information is available

• Core Expertise: BIOTYPE is known for being an innovative solution provider in molecular precision diagnostics, offering PCR-multiplex applications and molecular diagnostic products and services for professional laboratories globally.

Products

MODAPLEX Platform

• Description: The MODAPLEX platform is a proprietary bench-top system facilitating comprehensive multi-biomarker testing in a single, integrated workflow for molecular diagnostics.

• Key Features:

• Facilitates automated molecular profiling and multi-gene tests.

• Integrates seamlessly with laboratory workflows, providing results on the same day.

• Supports molecular diagnostics across applications in hemato-oncology and oncology research.

Custom Solutions

• Description: BIOTYPE offers premium contract development and manufacturing services, covering stages from the initial idea to a commercial product.

• Key Features:

• High-quality IVD-compliant services.

• Tailors development and manufacturing solutions for clients in various sectors including IVD, pharma, and biotech.

Hemato-Oncology Diagnostics

• Description: Offers molecular diagnostics for Acute Myeloid Leukemia (AML) and chimerism monitoring post-allogeneic stem cell transplantation.

• Key Features:

• Robust analysis aimed at improved diagnostic and treatment decision-making in hematology oncology.

Molecular Profiling

• Description: Provides reliable and robust molecular genetic tests designed for clinical research and oncology diagnostics.

• Key Features:

• Supports clinical trials and translational research with advanced molecular diagnostics.

Recent Developments

• New Products/Features Launched:

• MODAPLEX NRAS Mutation Kit: Launched on September 16, 2024, to detect 15 critical NRAS driver mutations crucial for first-line therapy decisions in advanced colorectal cancer (CRC).

• Multi-biomarker Assays for FGFR Alterations: Launched on August 27, 2024, for detecting actionable genetic alterations in bladder cancer samples.

• POLE/POLD1 Mutation Analysis Kit: The first scientific publication was presented on January 19, 2024.

• Partnerships:

• On June 23, 2023, a strategic collaboration with STRATIFYER Molecular Pathology GmbH to enhance precision medicine for bladder cancer patients was announced.

• A new distribution partnership with Gencurix, Inc., was announced on May 24, 2023, to promote molecular cancer diagnostics in Germany.

Values & Philosophy

• Vision: BIOTYPE envisions a world where every individual has easy access to precision diagnostics, enabling swift and precise diagnosis of complex diseases and facilitating targeted treatment decisions and effective therapies.

• Quality Management: Certified with ISO 9001:2015 & ISO 13485:2016 for its commitment to high-quality management across products, services, and processes.

• Core Values:

• Team Success: Emphasis on constructive collaboration across teams.

• Customer Orientation: Delivering great products and services that solve customer problems.

• Quality: Continuous improvement and sustainability.

• Responsibility: Ensuring product safety and efficacy.

• Innovation: Driving progress with new, market-relevant solutions.

Events

• Upcoming and Past Events:

• BIO-EUROPE 2024: November 4-6, 2024, Stockholm.

• MEDICA 2024: November 11-14, 2024, Düsseldorf.

• DGHO Annual Conference 2024: October 11-14, 2024, Basel.

• DGU Congress 2024: September 25-27, 2024, Leipzig.

For further information and continuous updates, refer to BIOTYPE's official communications or reach out to their professional contact channels.